期刊文献+

天门冬酰胺酶聚乙二醇-透明质酸/磺丁基-β-环糊精纳米粒体外稳定性的初步研究 被引量:1

Preliminary study on the stability of asparaginase loaded in self-assembly of polyethylene glycol-hyaluronic acid / sulfobutyl ether-β-cyclodextrin nanoparticles
原文传递
导出
摘要 目的制备含载天门冬酰胺酶(Asp)的自组装聚乙二醇-透明质酸/磺丁基-β-环糊精纳米粒(THSCD),并初步研究两者在体外的活性以及稳定性。方法采用自组装法制备THSCD;分别从最适温度、最适p H、酸碱稳定性、热稳定性、贮存稳定性、血浆稳定性、抗胰蛋白酶水解能力、部分金属离子及有机化合物影响来考察THSCD中Asp和游离Asp的差异。结果THSCD的最适温度为50℃,游离Asp最适温度为60℃。THSCD的最适p H为6.5,游离Asp的最适p H为7.5。THSCD的热稳定性、贮存稳定性、酸碱稳定性、血浆稳定性测定、抗胰蛋白酶水解能力和抗部分金属离子和有机化合物能力均比游离Asp好。结论 THSCD在提高了Asp在体外活性的同时,也明显地增强了游离Asp在体外的稳定性。 OBJECTIVE To prepare asparaginase( Asp) loaded in self- assembly of polyethylene glycol- hyaluronic acid / sulfobutyl ether- β- cyclodextrin nanoparticles( THSCD),and to investigate the in vitro activity and stability differences between THSCD and free Asp. METHODS THSCD was prepared by self- assembly method. To investigate the differences,the optimum temperature,optimum p H,acid and basic stabilities,thermal stability,storage stability,plasma stability,trypsin stability and effect of several metal ions and organic compounds on free Asp and THSCD were tested,by measuring the Asp activity. RESULTS The optimum temperature of THSCD was 50 ℃,The optimum temperature of free Asp was 60 ℃. The optimum p H of THSCD was 6. 5 and free Asp was 7. 5. Thermal stability,storage stability,acid- and basic- stabilities,proteolytic stabilities,trypsin stability and effect of several metal ions and organic compounds of THSCD were all better than free Asp. CONCLUSION THSCD can improve the activity and significantly enhances the stability of free Asp in vitro.
出处 《华西药学杂志》 CAS CSCD 2016年第2期124-127,共4页 West China Journal of Pharmaceutical Sciences
基金 重庆市科学技术委员会资助项目(stc2015jcyj BX0027)
关键词 天门冬酰胺酶 自组装聚乙二醇-透明质酸/磺丁基-β-环糊精纳米粒 最适温度 最适p H 稳定性 Asparaginase Self-assembly of polyethylene glycol-hyaluronic acid / dimethyl-β-cyclodextrin nanoparticles Optimum temperature Optimum p H Stability
  • 相关文献

参考文献7

  • 1庞梦婷,连治国,吴彦卓,徐明波,姚文兵.聚乙二醇修饰门冬酰胺酶的研究进展[J].药物生物技术,2013,20(6):590-593. 被引量:2
  • 2Bachet J, Gay F, Mar6chal R, et al. Asparagine synthetase expres- sion and phase I study with L - Asparaginase encapsulated in red blood cells in patients with pancreatic adenocarcinoma [ J ]. Pancreas,2015,44(7) :1141 - 1147.
  • 3Yao G, Zhou D, Zhou M, et al. Clinical analysis and prognostic significance of L - asparaginase containing muhidrug chemothera- py regimen in incipient peripheral T - cell lymphoma [ J ]. Int J Clin Exp Meal,2015,8(6) :9374 -9383.
  • 4Ha W, Meng X, Li Q, et al. Self i assembly hollow nanosphere for enzyme encapsulation [ J ]. Soft Matter,2010,6 (7) : 1405 - 1408.
  • 5Li Q, Xia B, Branham M, et al. Self - assembly of carboxymethyl konjac glucomannan - g - poly( ethylene glycol) and(α - cyclo- Dextrin) to biocompatible hollow nanospheres for glucose oxidase encapsulation [ J ]. Carbohydrate Polymers, 2011,86 ( 1 ) : 120 - 126.
  • 6施特尔马赫著 钱嘉渊译.酶的测定方法[M].北京:中国轻工业出版社,1992.102-119.
  • 7王娜,赵春景,黄开顺,滕永真,张景勍.产朊假丝酵母尿酸酶脂质纳米粒的制备及其药效学特性分析[J].中国生物制品学杂志,2013,26(8):1147-1150. 被引量:15

二级参考文献36

  • 1韦玉军,陈建华,吴梧桐.E.coli L-天冬酰胺酶结构与功能及其纯化工艺[J].药学进展,2005,29(9):397-404. 被引量:5
  • 2孟尧,辛渝,谭晓晶,许晓燕,余彩霞,杨波,孟延发.朊圆酵母尿酸酶的基本特性研究[J].四川大学学报(自然科学版),2006,43(2):414-419. 被引量:6
  • 3公伟,薛春佳,冯军,赵文杰.单甲氧基聚乙二醇修饰L-门冬酰胺酶的研究[J].中国医药工业杂志,2007,38(5):336-339. 被引量:5
  • 4Ernst ME, Fravel MA. Febuxostat: a selective xanthine-oxidase / xanthine-dehydrogenase inhibitor for the management of hype- ruricemia in adults with gout [J]. Clin Ther, 2009, 31 (11): 2503-2518.
  • 5Lu W, Song K, Wang Y, et ol. Relationship between serum uric acid and metabolic syndrome: an analysis by structural equation modeling [J]. J Clin Lipidol, 2012, 6 (2): 159-167.
  • 6Sherman MR, Saifer MG, Perez-Ruiz F. PEG-uricase in the management of treatment-resistant gout and hyperuricemia [J]. Adv Drug Deliver Rev, 2008, 60 ( 1 ): 59-65.
  • 7Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hype- ruricemia in the US general population: NHANES 2007-2008 [J]. Am J Med, 2012, 125 (7): 679-687.
  • 8Freitas Dda S, Spencer PJ, Vassao RC, et al. Biochemical and biopharmaceutical properties of PEGylated uricase [ J ]. Int J Pharm, 2010, 387 (1-2): 215-222.
  • 9Joshi MD, Mtiller RH. Lipid nanoparticles for parenteral delivery of actives [J]. Eur J Pharm Biopharm, 2009, 71 (2): 161-172.
  • 10Bradford MM. A rapid and sensitive method for the quanti- tation of microgram quantities of protein utilizing the principle of protein-dye binding [J]. Anal Biochem, 1976, 72(5): 248- 254.

共引文献24

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部